Who is sponsoring NCT03122730?

NCT03122730 is sponsored by Aerogen Pharma Limited.

What condition does NCT03122730 study?

NCT03122730 studies Pulmonary Hypertension.

What is the status of NCT03122730?

NCT03122730 is currently COMPLETED.

Last reviewed 2025-07-31 · How we verify

VentaProst Versus Conventionally-Administered Aerosolized Epoprostenol in Patients Undergoing Cardiac Surgery With CPB

NCT03122730 PHASE2 COMPLETED Results posted

The purpose of the Phase 2a study is to: 1) demonstrate that the estimated VentaProst dose is safe and equivalent in effect to a dose administered via epoprostenol aerosolization by the current off-label-use practice; and 2) demonstrate that an optimum effect can be rapidly obtained with VentaProst titration.

Details

Lead sponsor	Aerogen Pharma Limited
Phase	PHASE2
Status	COMPLETED
Enrolment	17
Start date	Wed Aug 23 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu May 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Pulmonary Hypertension

Interventions

VentaProst

Countries

United States